SCARB1 and cancer: As such, the ability of rHDL/sHDL to deplete cellular cholesterol and target SR-BI along with the biocompatibility of the individual components and proven clinical safety has enhanced the interest of developing rHDL/sHDL constructs in different medical areas, such as cancer, where HDL-like particles are being used for anti-cancer therapeutics and tumor imaging chemotherapy [116].